Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia

Abstract : Suboptimal drug adherence represents a major challenge to effective primary and secondary prevention of cardiovascular disease. While adherence is influenced by multiple considerations, polypharmacy and dosing frequency appear to be rate-limiting factors in patient satisfaction and subsequent adherence. The cardiovascular and metabolic therapeutic areas have recently benefited from a number of advances in drug therapy, in particular protease proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incretin-based therapies, respectively. These drugs are administered subcutaneously and offer efficacious treatment options with reduced dosing frequency. Whilst patients with diabetes and diabetologists are well initiated to injectable therapies, the cardiovascular therapeutic arena has traditionally been dominated by oral agents. It is therefore important to examine the practical aspects of treating patients with these new lipid-lowering agents, to ensure they are optimally deployed in everyday clinical practice.
Liste complète des métadonnées

Littérature citée [68 références]  Voir  Masquer  Télécharger
Contributeur : Gestionnaire Hal-Upmc <>
Soumis le : mercredi 30 août 2017 - 10:28:37
Dernière modification le : jeudi 24 mai 2018 - 15:58:12


Publication financée par une institution


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale 4.0 International License




Franck Boccara, Ricardo Dent, Luis Ruilope, Paul Valensi. Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. Advances in Therapy, Springer Verlag (Germany), 2017, 34 (8), pp.1876-1896. 〈10.1007/s12325-017-0586-8〉. 〈hal-01578948〉



Consultations de la notice


Téléchargements de fichiers